NCT03023202Recruiting

UWCCC Molecular Tumor Board Registry

University of Wisconsin, Madison

Start Date

3/30/2016

Completion Date

3/1/2029

Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Clinically suspected or histologically confirmed solid or hematological malignancy * Undergoing genetic testing of tumor * Ability to understand written informed consent document * Willingness to sign written informed consent document Exclusion Criteria: * Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Interventions

OTHER

PMMTB (Precision Medicine Molecular Tumor Board)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Hematologic NeoplasmsSolid Neoplasm

Locations

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin 53792

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.